Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Frontiers in oncology（2023）
摘要
Both the therapeutic and diagnostic scenarios have changed over the last couple of years in MITO centers, with an increased prescription of immune checkpoint inhibitors and use of the molecular classification.
更多查看译文
关键词
endometrial cancer, molecular classification, immune checkpoint inhibitors, dostarlimab, pembrolizumab plus lenvatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要